An international collaborative study led by scientists at Sweden’s Lund University has classified Alzheimer’s disease into four distinct subtypes, which has important implications for the management of the progressive neurodegenerative disease, the authors reported in the April 29, 2021, edition of Nature Medicine.
Using advanced intravital microscopy to visualize immune cell movement within the tissues, investigators at the Peter Doherty Institute for Infection and Immunity, Melbourne have discovered that the neurotransmitter noradrenaline produced by the sympathetic nervous system causes a dramatic paralysis of immune cell movement.
Researchers have gained new insights into what makes for transplantable livers – and what doesn’t. In a clinical trial of 12 livers, a team from Massachusetts General Hospital showed that both livers with high fat content and those without could be viable for transplantation.
A collaboration aimed at identifying and developing potential new antimalarial drug candidate drugs has been announced between Walter and Eliza Hall Institute for Medical Research in Melbourne, Australia, and Janssen Pharmaceutica, with assistance from Johnson & Johnson Innovation. The collaboration has already discovered promising compounds with antimalarial activity from among 80,000 drug-like molecules in the Janssen Jumpstarter Compound Library, a collection of drug-like compounds designed to fast-track discovery of new medicines.
Twenty years after the first, exclusively white human genomes were fully sequenced, science finds itself in the same position as the rest of society: with the uncomfortable realization that old inequalities are often morphing, rather than disappearing.
The enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in the regulation of blood LDL cholesterol levels. Now, new research shows that targeting PCSK9 may also potentiate checkpoint blockade.
DUBLIN – A newly published retrospective analysis of the electronic health care records of more than 500,000 COVID-19 patients has found that infection with SARS-CoV-2 carries “a significantly and substantially” greater risk of cerebral venous thrombosis (CVT) than does either one of the two approved mRNA COVID-19 vaccines or infection with influenza virus.